Clinical Trials Logo

Graves Ophthalmopathy clinical trials

View clinical trials related to Graves Ophthalmopathy.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT04040894 Approved for marketing - Thyroid Eye Disease Clinical Trials

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

EAP
Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or satisfactory alternative therapy for treatment.